Ocugen (OCGN) announced the appointment of Quan Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline. Prior to joining Ocugen, Vu served as Chief Operating Officer/Chief Business Officer for 180 Life Sciences (ATNF).
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OCGN:
- Ocugen Delivers Promising Covaxin Results in the U.S
- Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
- Ocugen reports ‘positive’ data from Phase 2/3 trial of COVAXIN
- Largest borrow rate increases among liquid names
- Ocugen: FDA agrees to control, design for Phase 3 study of NeoCart